Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9075261 | 0.76 | ESR1 (0.41) | SLC6A4SLC6A3CA1CA2TSHR | |
| SCHEMBL9066610 | 0.73 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL6449784 | 0.71 | CA1 (0.33) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL6449774 | 0.71 | CA1 (0.33) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL6449782 | 0.71 | CA1 (0.33) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL9073517 | 0.71 | ESR1 (0.37) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL9066311 | 0.70 | ESR2 (0.45) | SLC6A4SLC6A3CA1CA2TSHR | |
| SCHEMBL6056663 | 0.70 | ESR1 (0.38) | SLC6A4SLC6A3CA1CA2TSHR | |
| SCHEMBL6139573 | 0.68 | CYP2D6 (0.42) | SLC6A4SLC6A3SLC6A2CA1CA2 | |
| SCHEMBL6056626 | 0.68 | CA1 (0.37) | SLC6A4SLC6A3SLC6A2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | HUANG LIREN (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | ALK, CYP11B2, ALKBH2 | SLC6A4 2174/4885SLC6A3 1807/4885SLC6A2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.